EUCTR2013-003579-36-IT进行中（未招募）1 期
A multi-center, open-label, non-randomized, phase I dose escalation study ofregorafenib (BAY 73-4506) in pediatric subjects with solid malignant tumors that are recurrent or refractory to standard therapy.
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 50
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •- Signed Informed Consent Form by subjects and/or subjects’ parents/legal guardians and age appropriate Assent Form by the subjects obtained before any study specific procedure
- •- Age: from 5 years to less than 18 years old
- •- Pediatric subjects who are able to swallow tablets
- •- Diagnosis: subjects must have had histologic verification of solid malignancy at original diagnosis. Subjects with recurrent or refractory solid tumors are eligible, including primary CNS tumors or subjects with known CNS metastases
- •- Subject’s current disease state must be one for which there is no known effective therapy or therapy proven to prolong survival with an acceptable quality of life. Effective therapy may include surgery, radiation therapy, chemotherapy or any combination of these modalities.
- •- Sexually active females of childbearing potential and sexually active males must agree to use adequate contraception before entering the program until at least 8 weeks after the last study drug administration. Abstinence is considered an adequate contraception method. For sexually active females, 2 forms of highly effective contraception are mandatory. The investigator or a designated associate is requested to advise the subject on how to achieve an adequate birth control. Adequate contraception is defined in the study as any medically
- •recommended method (or combination of methods) as per standard of care.
- •- Female subjects of childbearing potential must have a pregnancy test performed a maximum of 7 days before start of study treatment, and a negative result must be documented before start of study treatment.
- •- Subjects must have at least one measurable or evaluable lesion according to Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1. For neuroblastoma subjects with osteomedullary disease, the SIOPEN (International Society of Pediatric Oncology Europe Neuroblastoma Group) score will be used.
- •- Life expectancy of at least 12 weeks from the time of signing informed
- •consent/assent
- •- Performance level: Karnofsky = 70% for subjects > 10 years of age and Lansky = 70% for subjects = 10 years of age, except children with motor paresis due to disease. Neurological deficits in subjects must have been stable for a minimum of 1 week prior to first dose of study treatment.
- •- Subjects with brain tumors or brain metastases must be on stable dose of corticosteroids for at least 1 week prior to first dose of study treatment.
- •- Adequate hematological function assessed by the following laboratory
- •requirements conducted within 7 days before starting study treatment:
- •o Peripheral absolute neutrophil count (ANC): = 1.0 x 10 9/L
- •o Platelet count : = 100 x 109/L (transfusion independent)
- •o Hemoglobin : = 8.0 g/ dL
- •- Adequate renal function defined as creatinine clearance based on Schwartz Estimate = 70 ml/min/1.73 m2 (1)
- •- International normalized ratio (INR) = 1.5 x upper limit of normal (ULN) and partial thromboplastin time (PTT) or activated partial thromboplastin time (aPTT) = 1.5 x ULN
- •- Lipase = 1.5 x ULN
- •- Adequate hepatic function defined as:
- •o Aspartate aminotransferase/alanine aminotransferase (AST/ALT)
- •=3.0 x ULN
- •o Bilirubin (sum of conjugated and unconjugated) = 1.5 ULN
- •o Alkaline phosphatase limit = 2.5 x ULN for age (= 5 x ULN for
- •subjects with bone tumors)
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range: 50
- •F.1.2 Adults (18-64 years) no
- •F.1.2.1 Numb
排除标准
- •- Prior treatment with regorafenib. Subjects permanently withdrawn from study participation will not be allowed to re-enter the study.
- •- Active or uncontrolled infection (> National Cancer Institute Common
- •Terminology Criteria for Adverse Events [NCI-CTCAE] Grade 2 at screening).
- •- Active hepatitis B or C, or chronic hepatitis B or C requiring treatment with antiviral therapy
- •- Known history of human immunodeficiency virus (HIV) infection
- •- Major surgical procedure or significant traumatic injury within 28 days before start of study medication. Bone marrow biopsy and central lines will not be considered as a major surgical procedure.
- •- Non-healing wound, ulcer, or bone fracture
- •- Seizure disorder requiring medication with: carbamazepine, phenobarbital, phenytoin, ethosuximide, valproic acid, tiagabine, felbamate, tiagabine, zomisamide and lamotrigine. Subjects with history of seizures controlled with levetiracetam or gabapentin and subjects with brain tumors receiving prophylactic levetiracetam or gabapentin are allowed to enter the study.
- •- Subjects with uncontrolled baseline hypertension higher than Grade 1 NCICTCAE v.4.0 (recurrent or persistent [=24 hours] blood pressure [BP] >ULN: BP > the 95th percentile for age, height, and gender measured as described in Appendix 14.5). Additional information about hypertension is provided in Appendix 14.6.
- •- Clinically significant bleeding (NCI-CTCAE v. 4.0 Grade 3 or higher) within 30 days before start of study medication
- •- Arterial or venous thrombotic or embolic events such as deep vein thrombosis or pulmonary embolism within 6 months before start of study medication (except for adequately treated catheter-related venous thrombosis occurring more than 1 month before the start of study medication)
- •- Subjects with evidence or history of disorders of coagulation or thrombosis
- •- Cardiac abnormalities such as congestive heart failure (Modified Ross Heart Failure Classification for Children = class 2) and cardiac arrhythmias requiring anti-arrhythmic therapy (beta blockers or digoxin are permitted)
- •- History of organ allograft (including allogeneic bone marrow transplant)
- •- Unresolved toxicity higher than NCI-CTCAE v. 4.0 Grade 1 attributed to any prior therapy/procedure (excluding alopecia, chemotherapy-induced ototoxicity, Grade 2 chemotherapy-induced neuropathy and, as per above eligibility criteria, anemia with hemoglobin = 8 mg/dL and ANC = 1.0 x 10 9/L )
- •- Pleural effusion or ascites that causes respiratory compromise (NCI-CTCAE v. 4.0 Grade 2 dyspnea)
- •- Known hypersensitivity to any of the study drugs, study drug classes, or
- •excipients in the formulation
- •- Pregnancy or breast feeding
- •- Significant gastrointestinal disorders with diarrhea as a major symptom e.g., Crohn’s disease or any malabsorption condition
- •- Interstitial lung disease with ongoing signs and symptoms at the time of screening
- •- Any other serious or unstable illness, or medical, psychological or social
- •condition, that could jeopardize the safety of the subject and/or his/her
- •compliance with study procedures, or may interfere with the subject’s
- •participation in the study or evaluation of the study results
- •- Close affiliation with the investigational site, e.g. a close relative of the
- •investigator or a dependent person (e.g. employee or student of the
- •investigational site)
研究者
相似试验
进行中（未招募）
1 期
Safety, tolerability and pharmacokinetics of regorafenib in pediatric subjects.Pediatric patients with solid malignant tumors that are recurrent or refractory to standard therapy.EUCTR2013-003579-36-FRBayer HealthCare AG50
进行中（未招募）
1 期
Safety, tolerability and pharmacokinetics of regorafenib in pediatric subjects.RMS and other solid malignant tumors (Ewing sarcoma, hepatoblastoma, neuroblastoma and Wilms tumor) in which treatment with vincristine/irinotecan is considered backbone chemotherapy at relapse and a scientific rationale to combine irinotecan with regorafenib exists.MedDRA version: 21.1Level: LLTClassification code 10065147Term: Malignant solid tumorSystem Organ Class: 100000004864EUCTR2013-003579-36-GBBayer AG77
未知
2 期
A multi-center, open label, non-randomized, phase II study to assess the activity and safety of cetuximab plus irinotecan in subjects with EGFR-detectable metastatic colorectal carcinomaColorectal carcinomaJPRN-jRCT2080220192Bristol-Myers K.K.38
进行中（未招募）
1 期
A Randomized, Open-label, Multicenter, Multiphase Study of JNJ-63723283, an Anti-PD-1 Monoclonal Antibody, Administered in Combination with Daratumumab, Compared with Daratumumab Alone in Subjects with Relapsed or Refractory Multiple Myeloma.EUCTR2017-002611-34-FRJanssen-Cilag International N.V.386
进行中（未招募）
1 期
A Randomized, Open-label, Multicenter, Multiphase Study of JNJ-63723283, an Anti-PD-1 Monoclonal Antibody, Administered in Combination with Daratumumab, Compared with Daratumumab Alone in Subjects with Relapsed or Refractory Multiple Myeloma.Relapsed or Refractory Multiple Myeloma (MM).MedDRA version: 21.0Level: LLTClassification code 10028228Term: Multiple myelomaSystem Organ Class: 100000004864EUCTR2017-002611-34-BEJanssen-Cilag International N.V.386